A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults

Inclusion Criteria: * 1\) Healthy volunteers, both male and female; * 2\) age: 18-45 years old; * 3\) Weight: Male ≥ 50kg, female ≥ 45kg, 19 ≤ BMI ≤ 26 (BMI=weight (kg)/height2 (m2); * 4\) Subject is in generally good health according to physical examination; * 5\) Subjects voluntarily participate in clinical trials and sign a written informed consent form. Exclusion Criteria: * 1\) Participated in any other clinical trial of drugs within the three months prior to the trial; * 2\) Any disease that may affect the safety of the clinical trial or the in vivo process of the investigational drug; * 3\) Allergic constitution: If there is a history of drug, food allergies, or skin allergies; * 4\) Any drug that inhibits or induces liver metabolism has been used within 28 days prior to the use of the investigational drug; * 5\) Have used any medication (including Chinese herbal medicine) and health supplements within 14 days prior to administration; * 6\) Have special requirements for diet and cannot follow a unified diet; * 7\) Subjects with a history of intolerance to venipuncture blood collection, or fear of needles and hemophobia; * 8\) Drinking alcohol, tea, or caffeinated beverages for a long period of time or within 48 hours prior to administration; * 9\) Previous alcoholics, or frequent alcohol consumption within 6 months prior to administration; or consumption of any alcohol-containing product within 24 hours prior to administration ; * 10\) Blood donation or blood loss (greater than 450 mL) within 3 months prior to administration, or planning to donate blood during the study period or within 3 months after the end of the study ; * 11\) Acute illness occurred during pre study screening or prior to administration; * 12\) Subjects who have any diet that can alter liver enzymes activity within 24 hours prior to administration; * 13\) Have undergone surgery within the first three months of screening, or plan to undergo surgery during the study period; * 14\) Previous drug addict and drug abuse; * 15\) Smoking more than 5 cigarettes per day within the first 14 days of screening, or unable to withdraw nicotine-containing products during the study; * 16\) Subjects who smoke or use nicotine-containing products from screening to hospitalization; * 17\) Abnormal and clinically significant electrocardiogram results before screening or administration, or QTcF(QTcF - Fridericia's correction formula)\>450 msec; * 18\) Positive results of nicotine test; * 19\) Alcohol breath test, with test results greater than 0.0mg/100 mL; * 20\) Positive urine drug test at screening; * 21\) Pregnant or lactating women; * 22\) Have plan for fertility or reluctance use any contraception during the study period and within 6 months after the end of the trial; * 23\) Subjects with other factors that are not suitable for participation in this study as judged by the investigator.